Publications based on CRC1479 funding

Raute K, Strietz J, Parigiani MA, Andrieux G, Thomas OS, Kistner KM, Zintchenko M, Aichele P, Hofmann M, Zhou H, Weber W, Boerries M, Swamy M, Maurer J, Minguet S. Breast Cancer Stem Cell-Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands. Cancer Immunol Res. 2023 May 4:OF1-OF20. doi: 10.1158/2326-6066.CIR-22-0296. Epub ahead of print.

Zeiser R, Chen YB, Youssef NN, Ayuk F. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2. Br J Haematol. 2023 May;201(4):620-627. 2023. doi: 10.1111/bjh.18778.

Langenbach M, Giesler S, Richtsfeld S, da Costa-Pereira S, Rindlisbacher L, Wertheimer T, Braun LM, Andrieux G, Duquesne S, Pfeifer D, Woessner NM, Menssen HD, Taromi S, Duyster J, Boerries M, Brummer T, Blazar BR, Minguet S, Turko P, Levesque MP, Becher B, Zeiser R. MDM2 inhibition enhances immune checkpoint inhibitor efficacy by increasing IL-15 and MHC class II production. Mol Cancer Res. 2023 Apr 18:MCR-22-0898. doi: 10.1158/1541-7786.MCR-22-0898. Epub ahead of print.

Petry P, Oschwald A, Kierdorf K. Microglial tissue surveillance: The never-resting gardener in the developing and adult CNS. Eur J Immunol. 2023 Jul;53(7):e2250232. doi: 10.1002/eji.202250232. Epub 2023 May 5.

Mohl DA, Lagies S, Zodel K, Zumkeller M, Peighambari A, Ganner A, Plattner DA, Neumann-Haefelin E, Adlesic M, Frew IJ, Kammerer B. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells. 2023 Apr 7;12(8):1102. doi: 10.3390/cells12081102.

Kocsmár É, Schmid M, Cosenza-Contreras M, Kocsmár I, Föll M, Krey L, Barta BA, Rácz G, Kiss A, Werner M, Schilling O, Lotz G, Bronsert P. Proteome alterations in human autopsy tissues in relation to time after death. Cell Mol Life Sci. 2023 Apr 5;80(5):117. doi: 10.1007/s00018-023-04754-3.

Stillger MN, Chen CY, Lai ZW, Li M, Schäfer A, Pagenstecher A, Nimsky C, Bartsch JW, Schilling O. Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. Cancer Cell Int. 2023 Mar 17;23(1):49. doi: 10.1186/s12935-023-02889-8.

Mass E, Nimmerjahn F, Kierdorf K, Schlitzer A. Tissue-specific macrophages: how they develop and choreograph tissue biology. Nat Rev Immunol. 2023 Mar 15:1–17. doi: 10.1038/s41577-023-00848-y. Epub ahead of print.

Edwards-Hicks J, Apostolova P, Buescher JM, Maib H, Stanczak MA, Corrado M, Klein Geltink RI, Maccari ME, Villa M, Carrizo GE, Sanin DE, Baixauli F, Kelly B, Curtis JD, Haessler F, Patterson A, Field CS, Caputa G, Kyle RL, Soballa M, Cha M, Paul H, Martin J, Grzes KM, Flachsmann L, Mitterer M, Zhao L, Winkler F, Rafei-Shamsabadi DA, Meiss F, Bengsch B, Zeiser R, Puleston DJ, O’Sullivan D, Pearce EJ, Pearce EL. Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function. Nat Immunol. 2023 Mar;24(3):516-530. doi: 10.1038/s41590-023-01419-y. Epub 2023 Feb 2.

Socie G, Niederwieser D, von Bubnoff N, Mohty M, Szer J, Or R, Garrett J, Prahallad AC, Wilke C, Zeiser R. Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis. Blood. 2023 Feb 24:blood.2022018579. doi: 10.1182/blood.2022018579.

Zeiser R. Novel Approaches to the Treatment of Chronic Graft-Versus-Host Disease.  J Clin Oncol. 2023 Feb 17:JCO2202256. doi: 10.1200/JCO.22.02256.

Amann L, Masuda T, Prinz M. Mechanisms of myeloid cell entry to the healthy and diseased central nervous system. Nat Immunol. 2023 Mar;24(3):393-407. doi: 10.1038/s41590-022-01415-8. Epub 2023 Feb 9.

Boonsanay V, Mosa MH, Looso M, Weichenhan D, Ceteci F, Pudelko L, Lechel A, Michel CS, Künne C, Farin HF, Plass C, Greten FR. Loss of SUV420H2-Dependent Chromatin Compaction Drives Right-Sided Colon Cancer Progression. Gastroenterology. 2023 Feb;164(2):214-227. doi: 10.1053/j.gastro.2022.10.036.

Conche C, Finkelmeier F, Pešić M, Nicolas AM, Böttger TW, Kennel KB, Denk D, Ceteci F, Mohs K, Engel E, Canli Ö, Dabiri Y, Peiffer KH, Zeuzem S, Salinas G, Longerich T, Yang H, Greten FR. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023 Jan 27:gutjnl-2022-327909. doi: 10.1136/gutjnl-2022-327909. Epub ahead of print.

Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack TM, Kissel S, Pfeifer D, Zeiser R, Fisch P, Andrieux G, Bräuer-Hartmann D, Bauer M, Schulze S, Follo M, Boerries M, von Bubnoff N, Miething C, Hidalgo JV, Klein C, Weber T, Wickenhauser C, Binder M, Dierks C. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood. 2023 Jan 25:blood.2022015653. doi: 10.1182/blood.2022015653.

Neuwirt E, Magnani G, Ćiković T, Wöhrle S, Fischer L, Kostina A, Flemming S, Fischenich NJ, Saller BS, Gorka O, Renner S, Agarinis C, Parker CN, Boettcher A, Farady CJ, Kesselring R, Berlin C, Backofen R, Rodriguez-Franco M, Kreutz C, Prinz M, Tholen M, Reinheckel T, Ott T, Groß CJ, Jost PJ, Groß O. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. Sci Signal. 2023 Jan 17;16(768):eabh1083. doi: 10.1126/scisignal.abh1083. Epub 2023 Jan 17.

Werner J, Bernhard P, Cosenza-Contreras M, Pinter N, Fahrner M, Pallavi P, Eberhard J, Bronsert P, Rückert F, Schilling O. Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling. Neoplasia. 2023 Feb;36:100871. doi: 10.1016/j.neo.2022.100871. Epub 2023 Jan 5.

Koistinen H, Kovanen RM, Hollenberg MD, Dufour A, Radisky ES, Stenman UH, Batra J, Clements J, Hooper JD, Diamandis E, Schilling O, Rannikko A, Mirtti T. The roles of proteases in prostate cancer. IUBMB Life. 2023 Jun;75(6):493-513. doi: 10.1002/iub.2700. Epub 2023 Jan 4.

Seidel P, Rubarth A, Zodel K, Peighambari A, Neumann F, Federkiel Y, Huang H, Hoefflin R, Adlesic M, Witt C, Hoffmann DJ, Metzger P, Lindemann RK, Zenke FT, Schell C, Boerries M, von Elverfeldt D, Reichardt W, Follo M, Albers J, Frew IJ. ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma. JCI Insight. 2022 Dec 22;7(24):e156087. doi: 10.1172/jci.insight.156087. PMID: 36413415; PMCID: PMC9869969.

Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S, Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 2022 Dec 21;14(676):eabp9675. doi: 10.1126/scitranslmed.abp9675. Epub 2022 Dec 21. PMID: 36542690.

free full text: https://www.science.org/stoken/author-tokens/ST-951/full